TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04176198: A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

Sponsor: Sumitomo Pharma America, Inc. · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 240 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,258,025

Rescue Site Savings

+$1,495,575

Unlock Full NCT04176198 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04176198 Rescue Dossier →